Insider Transactions in Q2 2021 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.61%
|
$90,000
$90.02 P/Share
|
|
Jun 28
2021
|
Kate Haviland Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Jun 02
2021
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,292
-4.23%
|
$114,988
$89.03 P/Share
|
|
Jun 02
2021
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+5.37%
|
-
|
|
Jun 02
2021
|
Alexis Borisy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+3.26%
|
-
|
|
Jun 02
2021
|
Lynn Seely Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Charles A Rowland Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
George Demetri |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Lonnel Coats Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 01
2021
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,843
+50.0%
|
-
|
|
Jun 01
2021
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
237
-2.29%
|
$21,567
$91.67 P/Share
|
|
May 17
2021
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,055
-23.23%
|
$290,225
$95.0 P/Share
|
|
May 17
2021
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,350
+5.01%
|
$6,750
$5.34 P/Share
|
|
May 12
2021
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
25,000
-4.36%
|
$2,300,000
$92.61 P/Share
|
|
May 12
2021
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.07%
|
$200,000
$8.44 P/Share
|